Myc Explained

MYC proto-oncogene, bHLH transcription factor
Symbol:MYC
Altsymbols:c-Myc, v-myc
Entrezgene:4609
Hgncid:7553
Omim:190080
Refseq:NM_001354870.1
Uniprot:P01106
Chromosome:8
Arm:q
Band:24.21
Wikidata:Q20969939
MYCL proto-oncogene, bHLH transcription factor
Symbol:MYCL
Altsymbols:LMYC, MYCL1, bHLHe38, L-Myc, v-myc
Entrezgene:4610
Hgncid:7555
Omim:164850
Refseq:NM_005376
Uniprot:P12524
Chromosome:1
Arm:p
Band:34.2
Wikidata:Q18029714
MYCN proto-oncogene, bHLH transcription factor
Symbol:MYCN
Entrezgene:4613
Hgncid:7559
Omim:164840
Refseq:NM_005378
Uniprot:V
Chromosome:2
Arm:p
Band:24.3
Wikidata:Q14906753

Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc.

In cancer, c-myc is often constitutively (persistently) expressed. This leads to the increased expression of many genes, some of which are involved in cell proliferation, contributing to the formation of cancer.[1] A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma.[2] Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach.

Myc is thus viewed as a promising target for anti-cancer drugs.[3] Unfortunately, Myc possesses several features that have rendered it difficult to drug to date, such that any anti-cancer drugs aimed at inhibiting Myc may continue to require perturbing the protein indirectly, such as by targeting the mRNA for the protein rather than via a small molecule that targets the protein itself.[4] [5]

c-Myc also plays an important role in stem cell biology and was one of the original Yamanaka factors used to reprogram somatic cells into induced pluripotent stem cells.[6]

In the human genome, C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes[7] through binding on enhancer box sequences (E-boxes).

In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation.[8]

Discovery

The Myc family was first established after discovery of homology between an oncogene carried by the Avian virus, Myelocytomatosis (v-myc;) and a human gene over-expressed in various cancers, cellular Myc (c-Myc). Later, discovery of further homologous genes in humans led to the addition of n-Myc and l-Myc to the family of genes.[9]

The most frequently discussed example of c-Myc as a proto-oncogene is its implication in Burkitt's lymphoma. In Burkitt's lymphoma, cancer cells show chromosomal translocations, most commonly between chromosome 8 and chromosome 14 [t(8;14)]. This causes c-Myc to be placed downstream of the highly active immunoglobulin (Ig) promoter region, leading to overexpression of Myc.

Structure

The protein products of Myc family genes all belong to the Myc family of transcription factors, which contain bHLH (basic helix-loop-helix) and LZ (leucine zipper) structural motifs. The bHLH motif allows Myc proteins to bind with DNA, while the leucine zipper TF-binding motif allows dimerization with Max, another bHLH transcription factor.

Myc mRNA contains an IRES (internal ribosome entry site) that allows the RNA to be translated into protein when 5' cap-dependent translation is inhibited, such as during viral infection.

Function

Myc proteins are transcription factors that activate expression of many pro-proliferative genes through binding enhancer box sequences (E-boxes) and recruiting histone acetyltransferases (HATs). Myc is thought to function by upregulating transcript elongation of actively transcribed genes through the recruitment of transcriptional elongation factors.[10] It can also act as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication.[11] This activity could contribute to DNA amplification in cancer cells.[12]

Myc is activated upon various mitogenic signals such as serum stimulation or by Wnt, Shh and EGF (via the MAPK/ERK pathway).[13] By modifying the expression of its target genes, Myc activation results in numerous biological effects. The first to be discovered was its capability to drive cell proliferation (upregulates cyclins, downregulates p21), but it also plays a very important role in regulating cell growth (upregulates ribosomal RNA and proteins), apoptosis (downregulates Bcl-2), differentiation, and stem cell self-renewal. Nucleotide metabolism genes are upregulated by Myc,[14] which are necessary for Myc induced proliferation[15] or cell growth.[16]

There have been several studies that have clearly indicated Myc's role in cell competition.[17]

A major effect of c-myc is B cell proliferation, and gain of MYC has been associated with B cell malignancies and their increased aggressiveness, including histological transformation.[18] In B cells, Myc acts as a classical oncogene by regulating a number of pro-proliferative and anti-apoptotic pathways, this also includes tuning of BCR signaling and CD40 signaling in regulation of microRNAs (miR-29, miR-150, miR-17-92).[19]

c-Myc induces MTDH(AEG-1) gene expression and in turn itself requires AEG-1 oncogene for its expression.

Myc-nick

Myc-nick is a cytoplasmic form of Myc produced by a partial proteolytic cleavage of full-length c-Myc and N-Myc.[20] Myc cleavage is mediated by the calpain family of calcium-dependent cytosolic proteases.

The cleavage of Myc by calpains is a constitutive process but is enhanced under conditions that require rapid downregulation of Myc levels, such as during terminal differentiation. Upon cleavage, the C-terminus of Myc (containing the DNA binding domain) is degraded, while Myc-nick, the N-terminal segment 298-residue segment remains in the cytoplasm. Myc-nick contains binding domains for histone acetyltransferases and for ubiquitin ligases.

The functions of Myc-nick are currently under investigation, but this new Myc family member was found to regulate cell morphology, at least in part, by interacting with acetyl transferases to promote the acetylation of α-tubulin. Ectopic expression of Myc-nick accelerates the differentiation of committed myoblasts into muscle cells.

Clinical significance

A large body of evidence shows that Myc genes and proteins are highly relevant for treating tumors.[9] Except for early response genes, Myc universally upregulates gene expression. Furthermore, the upregulation is nonlinear. Genes for which expression is already significantly upregulated in the absence of Myc are strongly boosted in the presence of Myc, whereas genes for which expression is low in the absence Myc get only a small boost when Myc is present.[6]

Inactivation of SUMO-activating enzyme (SAE1 / SAE2) in the presence of Myc hyperactivation results in mitotic catastrophe and cell death in cancer cells. Hence inhibitors of SUMOylation may be a possible treatment for cancer.[21]

Amplification of the MYC gene was found in a significant number of epithelial ovarian cancer cases.[22] In TCGA datasets, the amplification of Myc occurs in several cancer types, including breast, colorectal, pancreatic, gastric, and uterine cancers.[23]

In the experimental transformation process of normal cells into cancer cells, the MYC gene can cooperate with the RAS gene.[24] [25]

Expression of Myc is highly dependent on BRD4 function in some cancers.[26] [27] BET inhibitors have been used to successfully block Myc function in pre-clinical cancer models and are currently being evaluated in clinical trials.[28]

MYC expression is controlled by a wide variety of noncoding RNAs, including miRNA, lncRNA, and circRNA. Some of these RNAs have been shown to be specific for certain types of human tissues and tumors.[29] Changes in the expression of such RNAs can potentially be used to develop targeted tumor therapy.

Animal models

In Drosophila Myc is encoded by the diminutive locus, (which was known to geneticists prior to 1935).[30] Classical diminutive alleles resulted in a viable animal with small body size. Drosophila has subsequently been used to implicate Myc in cell competition,[31] endoreplication,[32] and cell growth.[33]

During the discovery of Myc gene, it was realized that chromosomes that reciprocally translocate to chromosome 8 contained immunoglobulin genes at the break-point. To study the mechanism of tumorigenesis in Burkitt lymphoma by mimicking expression pattern of Myc in these cancer cells, transgenic mouse models were developed. Myc gene placed under the control of IgM heavy chain enhancer in transgenic mice gives rise to mainly lymphomas. Later on, in order to study effects of Myc in other types of cancer, transgenic mice that overexpress Myc in different tissues (liver, breast) were also made. In all these mouse models overexpression of Myc causes tumorigenesis, illustrating the potency of Myc oncogene.In a study with mice, reduced expression of Myc was shown to induce longevity, with significantly extended median and maximum lifespans in both sexes and a reduced mortality rate across all ages, better health, cancer progression was slower, better metabolism and they had smaller bodies. Also, Less TOR, AKT, S6K and other changes in energy and metabolic pathways (such as AMPK, more oxygen consumption, more body movements, etc.). The study by John M. Sedivy and others used Cre-Loxp -recombinase to knockout one copy of Myc and this resulted in a "Haplo-insufficient" genotype noted as Myc+/-. The phenotypes seen oppose the effects of normal aging and are shared with many other long-lived mouse models such as CR (calorie restriction) ames dwarf, rapamycin, metformin and resveratrol. One study found that Myc and p53 genes were key to the survival of chronic myeloid leukaemia (CML) cells. Targeting Myc and p53 proteins with drugs gave positive results on mice with CML.[34] [35]

Relationship to stem cells

Myc genes play a number of normal roles in stem cells including pluripotent stem cells. In neural stem cells, N-Myc promotes a rapidly proliferative stem cell and precursor-like state in the developing brain, while inhibiting differentiation.[36] In hematopoietic stem cells, Myc controls the balance between self-renewal and differentiation.[37] In particular, long-term hematopoietic stem cells (LT-HSCs) express low levels of c-Myc, ensuring self-renewal. Enforced expression of c-Myc in LT-HSCs promotes differentiation at the expense of self-renewal, resulting in stem cell exhaustion.[38] In pathological states and specifically in acute myeloid leukemia, oxidant stress can trigger higher levels of Myc expression that affects the behavior of leukemia stem cells.[39]

c-Myc plays a major role in the generation of induced pluripotent stem cells (iPSCs). It is one of the original factors discovered by Yamanaka et al. to encourage cells to return to a 'stem-like' state alongside transcription factors Oct4, Sox2 and Klf4. It has since been shown that it is possible to generate iPSCs without c-Myc.[40]

Interactions

Myc has been shown to interact with:

See also

Further reading

External links

Notes and References

  1. Web site: Myc . NCBI .
  2. Finver SN, Nishikura K, Finger LR, Haluska FG, Finan J, Nowell PC, Croce CM . Sequence analysis of the Myc oncogene involved in the t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates that putative regulatory regions are not altered . Proceedings of the National Academy of Sciences of the United States of America . 85 . 9 . 3052–6 . May 1988 . 2834731 . 280141 . 10.1073/pnas.85.9.3052 . 1988PNAS...85.3052F . free .
  3. Web site: DNA pioneer James Watson takes aim at cancer establishments . Reuters . Begley S . 2013-01-09 .
  4. Carabet LA, Rennie PS, Cherkasov A . Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches . International Journal of Molecular Sciences . 20 . 1 . December 2018 . 30597997 . 6337544 . 10.3390/ijms20010120 . 120. free .
  5. Dang CV, Reddy EP, Shokat KM, Soucek L . Drugging the 'undruggable' cancer targets . Nature Reviews. Cancer . 17 . 8 . 502–508 . August 2017 . 28643779 . 5945194 . 10.1038/nrc.2017.36 . Laura Soucek .
  6. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D . c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells . Cell . 151 . 1 . 68–79 . September 2012 . 23021216 . 3471363 . 10.1016/j.cell.2012.08.033 .
  7. Gearhart J, Pashos EE, Prasad MK . Pluripotency redux--advances in stem-cell research . The New England Journal of Medicine . 357 . 15 . 1469–72 . October 2007 . 17928593 . 10.1056/NEJMp078126 .
  8. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS . N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor . Cancer Research . 68 . 23 . 9654–62 . December 2008 . 19047142 . 2637654 . 10.1158/0008-5472.CAN-08-1961 .
  9. Wolf E, Eilers M . Targeting MYC Proteins for Tumor Therapy. 2020 . Annual Review of Cancer Biology. 4. 61–75 . 10.1146/annurev-cancerbio-030518-055826 . free.
  10. Rahl PB, Young RA . MYC and transcription elongation . Cold Spring Harbor Perspectives in Medicine . 4 . 1 . a020990 . January 2014 . 24384817 . 3869279 . 10.1101/cshperspect.a020990 .
  11. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R . Non-transcriptional control of DNA replication by c-Myc . Nature . 448 . 7152 . 445–51 . July 2007 . 17597761 . 10.1038/nature05953 . 2007Natur.448..445D . 4422771 .
  12. Denis N, Kitzis A, Kruh J, Dautry F, Corcos D . Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc . Oncogene . 6 . 8 . 1453–7 . August 1991 . 1886715 .
  13. Campisi J, Gray HE, Pardee AB, Dean M, Sonenshein GE . Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation . Cell . 36 . 2 . 241–7 . 1984 . 6692471 . 10.1016/0092-8674(84)90217-4 . 29661004 .
  14. Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N, Sedivy JM, Zeller KI, Dang CV . Global regulation of nucleotide biosynthetic genes by c-Myc . PLOS ONE . 3 . 7 . e2722 . July 2008 . 18628958 . 2444028 . 10.1371/journal.pone.0002722 . 2008PLoSO...3.2722L . free .
  15. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA . Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells . Cell Cycle . 7 . 15 . 2392–400 . August 2008 . 18677108 . 3744895 . 10.4161/cc.6390 .
  16. Aughey GN, Grice SJ, Liu JL . The Interplay between Myc and CTP Synthase in Drosophila . PLOS Genetics . 12 . 2 . e1005867 . February 2016 . 26889675 . 4759343 . 10.1371/journal.pgen.1005867 . free .
  17. Clavería C, Giovinazzo G, Sierra R, Torres M . Myc-driven endogenous cell competition in the early mammalian embryo . Nature . 500 . 7460 . 39–44 . August 2013 . 23842495 . 10.1038/nature12389 . 2013Natur.500...39C . 4414411 .
  18. de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW . Analysis of C-MYC function in normal cells via conditional gene-targeted mutation . Immunity . 14 . 1 . 45–55 . January 2001 . 11163229 . 10.1016/S1074-7613(01)00088-7 . free .
  19. Mendell JT . miRiad roles for the miR-17-92 cluster in development and disease . Cell . 133 . 2 . 217–22 . April 2008 . 18423194 . 2732113 . 10.1016/j.cell.2008.04.001 .
  20. Conacci-Sorrell M, Ngouenet C, Eisenman RN . Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation . Cell . 142 . 3 . 480–93 . August 2010 . 20691906 . 2923036 . 10.1016/j.cell.2010.06.037 .
  21. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF . A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis . Science . 335 . 6066 . 348–53 . January 2012 . 22157079 . 4059214 . 10.1126/science.1212728 . 2012Sci...335..348K .
  22. Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ . Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies . Gynecologic Oncology . 130 . 3 . 554–9 . September 2013 . 23791828 . 10.1016/j.ygyno.2013.06.019 . free .
  23. Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV, Buchanan S, Peng SB, Staschke KA, Yadav V, Yue Y, Kouros-Mehr H . Identification of druggable cancer driver genes amplified across TCGA datasets . PLOS ONE . 9 . 5 . e98293 . 2014 . 24874471 . 4038530 . 10.1371/journal.pone.0098293 . 2014PLoSO...998293C . free .
  24. Land H, Parada LF, Weinberg RA . Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes . Nature . 304 . 5927 . 596–602 . 1983 . 6308472 . 10.1038/304596a0 . 1983Natur.304..596L . 2338865 .
  25. Radner H, el-Shabrawi Y, Eibl RH, Brüstle O, Kenner L, Kleihues P, Wiestler OD . Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose . Acta Neuropathologica . 86 . 5 . 456–65 . 1993 . 8310796 . 10.1007/bf00228580 . 2972931 .
  26. Fowler T, Ghatak P, Price DH, Conaway R, Conaway J, Chiang CM, Bradner JE, Shilatifard A, Roy AL . Regulation of MYC expression and differential JQ1 sensitivity in cancer cells . PLOS ONE . 9 . 1 . e87003 . 2014 . 24466310 . 3900694 . 10.1371/journal.pone.0087003 . 2014PLoSO...987003F . free .
  27. Shi J, Vakoc CR . The mechanisms behind the therapeutic activity of BET bromodomain inhibition . Molecular Cell . 54 . 5 . 728–36 . June 2014 . 24905006 . 4236231 . 10.1016/j.molcel.2014.05.016 .
  28. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS . BET bromodomain inhibition as a therapeutic strategy to target c-Myc . Cell . 146 . 6 . 904–17 . September 2011 . 21889194 . 3187920 . 10.1016/j.cell.2011.08.017 .
  29. Stasevich EM, Murashko MM, Zinevich LS, Demin DE, Schwartz AM. The Role of Non-Coding RNAs in the Regulation of the Proto-Oncogene MYC in Different Types of Cancer . Biomedicines . 9 . 8 . 921 . July 2021 . 34440124. 8389562. 10.3390/biomedicines9080921. free .
  30. Slizynska H . Salivary Chromosome Analysis of the White-Facet Region of Drosophila Melanogaster . Genetics . 23 . 3 . 291–9 . May 1938 . 10.1093/genetics/23.3.291 . 17246888 . 1209013 .
  31. de la Cova C, Abril M, Bellosta P, Gallant P, Johnston LA . Drosophila myc regulates organ size by inducing cell competition . Cell . 117 . 1 . 107–16 . April 2004 . 15066286 . 10.1016/S0092-8674(04)00214-4 . 18357397 . free .
  32. Maines JZ, Stevens LM, Tong X, Stein D . Drosophila dMyc is required for ovary cell growth and endoreplication . Development . 131 . 4 . 775–86 . February 2004 . 14724122 . 10.1242/dev.00932 . 721144 .
  33. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P . Drosophila myc regulates cellular growth during development . Cell . 98 . 6 . 779–90 . September 1999 . 10499795 . 10.1016/S0092-8674(00)81512-3 . 10176494 . 5215149 . 2020-03-20 . 2022-04-03 . https://web.archive.org/web/20220403025727/https://www.zora.uzh.ch/id/eprint/740/1/Johnston_1999.pdf . dead .
  34. 6. Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL. June 2016. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 534. 7607. 341–6. 10.1038/nature18288. 4913876. 27281222. 2016Natur.534..341A.
  35. Web site: Scientists identify drugs to target 'Achilles heel' of Chronic Myeloid Leukaemia cells. 2016-06-08. myScience. 2016-06-09. 2018-07-27. https://web.archive.org/web/20180727212225/https://www.myscience.org.uk/news/2016/cientists_identify_drugs_to_target_achilles_heel_of_chronic_myeloid_leukaemia_cells-2016-glasgow. dead.
  36. Knoepfler PS, Cheng PF, Eisenman RN . N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation . Genes & Development . 16 . 20 . 2699–712 . October 2002 . 12381668 . 10.1101/gad.1021202 . 187459 . free .
  37. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A . 6 . c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation . Genes & Development . 18 . 22 . 2747–63 . November 2004 . 15545632 . 10.1101/gad.313104 . 528895 . free .
  38. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A . 6 . c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation . Genes & Development . 18 . 22 . 2747–63 . November 2004 . 15545632 . 10.1101/gad.313104 . 528895 . free .
  39. Vlahopoulos S, Pan L, Varisli L, Dancik GM, Karantanos T, Boldogh I . OGG1 as an Epigenetic Reader Affects NFκB: What This Means for Cancer . Cancers (Basel) . 16 . 1 . 148 . Dec 2023 . 38201575 . 10.3390/cancers16010148. free . 10778025 .
  40. Takahashi K, Yamanaka S . A decade of transcription factor-mediated reprogramming to pluripotency . Nature Reviews. Molecular Cell Biology . 17 . 3 . 183–93 . March 2016 . 26883003 . 10.1038/nrm.2016.8 . 7593915 .
  41. Xiong J, Fan S, Meng Q, Schramm L, Wang C, Bouzahza B, Zhou J, Zafonte B, Goldberg ID, Haddad BR, Pestell RG, Rosen EM . BRCA1 inhibition of telomerase activity in cultured cells . Molecular and Cellular Biology . 23 . 23 . 8668–90 . December 2003 . 14612409 . 262673 . 10.1128/mcb.23.23.8668-8690.2003 .
  42. Zhou C, Liu J . Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells . Biochemical and Biophysical Research Communications . 303 . 1 . 130–6 . March 2003 . 12646176 . 10.1016/s0006-291x(03)00318-8 .
  43. Wang Q, Zhang H, Kajino K, Greene MI . BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells . Oncogene . 17 . 15 . 1939–48 . October 1998 . 9788437 . 10.1038/sj.onc.1202403 . 30771256 .
  44. Jin Z, Gao F, Flagg T, Deng X . Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation . The Journal of Biological Chemistry . 279 . 38 . 40209–19 . September 2004 . 15210690 . 10.1074/jbc.M404056200 . free .
  45. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM . c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis . Oncogene . 22 . 36 . 5707–11 . August 2003 . 12944920 . 10.1038/sj.onc.1206800 . 29519364 .
  46. Dingar D, Kalkat M, Chan PK, Srikumar T, Bailey SD, Tu WB, Coyaud E, Ponzielli R, Kolyar M, Jurisica I, Huang A, Lupien M, Penn LZ, Raught B . BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors . Journal of Proteomics . 118 . 12 . 95–111 . April 2015 . 25452129 . 10.1016/j.jprot.2014.09.029 .
  47. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, Pelicci PG, Amati B, Kouzarides T, de Launoit Y, Di Croce L, Fuks F . Myc represses transcription through recruitment of DNA methyltransferase corepressor . The EMBO Journal . 24 . 2 . 336–46 . January 2005 . 15616584 . 545804 . 10.1038/sj.emboj.7600509 .
  48. Roy AL, Carruthers C, Gutjahr T, Roeder RG . Direct role for Myc in transcription initiation mediated by interactions with TFII-I . Nature . 365 . 6444 . 359–61 . September 1993 . 8377829 . 10.1038/365359a0 . 1993Natur.365..359R . 4354157 .
  49. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan HM, Livingston DM, Amati B . MYC recruits the TIP60 histone acetyltransferase complex to chromatin . EMBO Reports . 4 . 6 . 575–80 . June 2003 . 12776177 . 1319201 . 10.1038/sj.embor.embor861 .
  50. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT . Widespread microRNA repression by Myc contributes to tumorigenesis . Nature Genetics . 40 . 1 . 43–50 . January 2008 . 18066065 . 2628762 . 10.1038/ng.2007.30 .
  51. Koscianska E, Baev V, Skreka K, Oikonomaki K, Rusinov V, Tabler M, Kalantidis K . Prediction and preliminary validation of oncogene regulation by miRNAs . BMC Molecular Biology . 8 . 79 . 2007 . 17877811 . 2096627 . 10.1186/1471-2199-8-79 . free .
  52. Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M . CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells . The Journal of Biological Chemistry . 280 . 20 . 20086–93 . May 2005 . 15769738 . 10.1074/jbc.M410036200 . free .
  53. Gupta S, Davis RJ . MAP kinase binds to the NH2-terminal activation domain of c-Myc . FEBS Letters . 353 . 3 . 281–5 . October 1994 . 7957875 . 10.1016/0014-5793(94)01052-8 . 45404088 . free .
  54. Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ . Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase . Proceedings of the National Academy of Sciences of the United States of America . 94 . 14 . 7337–42 . July 1997 . 9207092 . 23822 . 10.1073/pnas.94.14.7337 . 1997PNAS...94.7337T . free .
  55. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y . Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase . The Journal of Biological Chemistry . 274 . 46 . 32580–7 . November 1999 . 10551811 . 10.1074/jbc.274.46.32580 . free .
  56. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D . Large-scale mapping of human protein-protein interactions by mass spectrometry . Molecular Systems Biology . 3 . 89 . 2007 . 17353931 . 1847948 . 10.1038/msb4100134 .
  57. McMahon SB, Wood MA, Cole MD . The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc . Molecular and Cellular Biology . 20 . 2 . 556–62 . January 2000 . 10611234 . 85131 . 10.1128/mcb.20.2.556-562.2000 .
  58. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD . The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins . Cell . 94 . 3 . 363–74 . August 1998 . 9708738 . 10.1016/s0092-8674(00)81479-8 . 17693834 . free .
  59. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV . c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function . Nature Genetics . 22 . 1 . 102–5 . May 1999 . 10319872 . 10.1038/8811 . 12945791 .
  60. Mac Partlin M, Homer E, Robinson H, McCormick CJ, Crouch DH, Durant ST, Matheson EC, Hall AG, Gillespie DA, Brown R . Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX . Oncogene . 22 . 6 . 819–25 . February 2003 . 12584560 . 10.1038/sj.onc.1206252 . free .
  61. Blackwood EM, Eisenman RN . Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc . Science . 251 . 4998 . 1211–7 . March 1991 . 2006410 . 10.1126/science.2006410 . 1991Sci...251.1211B .
  62. Lee CM, Onésime D, Reddy CD, Dhanasekaran N, Reddy EP . JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors . Proceedings of the National Academy of Sciences of the United States of America . 99 . 22 . 14189–94 . October 2002 . 12391307 . 137859 . 10.1073/pnas.232310199 . 2002PNAS...9914189L . free .
  63. Billin AN, Eilers AL, Queva C, Ayer DE . Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors . The Journal of Biological Chemistry . 274 . 51 . 36344–50 . December 1999 . 10593926 . 10.1074/jbc.274.51.36344 . free .
  64. Gupta K, Anand G, Yin X, Grove L, Prochownik EV . Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc . Oncogene . 16 . 9 . 1149–59 . March 1998 . 9528857 . 10.1038/sj.onc.1201634 . 30576019 .
  65. Meroni G, Reymond A, Alcalay M, Borsani G, Tanigami A, Tonlorenzi R, Lo Nigro C, Messali S, Zollo M, Ledbetter DH, Brent R, Ballabio A, Carrozzo R . Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor . The EMBO Journal . 16 . 10 . 2892–906 . May 1997 . 9184233 . 1169897 . 10.1093/emboj/16.10.2892 .
  66. Nair SK, Burley SK . X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors . Cell . 112 . 2 . 193–205 . January 2003 . 12553908 . 10.1016/s0092-8674(02)01284-9 . 16142388 . free .
  67. FitzGerald MJ, Arsura M, Bellas RE, Yang W, Wu M, Chin L, Mann KK, DePinho RA, Sonenshein GE . Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc . Oncogene . 18 . 15 . 2489–98 . April 1999 . 10229200 . 10.1038/sj.onc.1202611 . free .
  68. Meroni G, Cairo S, Merla G, Messali S, Brent R, Ballabio A, Reymond A . Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway? . Oncogene . 19 . 29 . 3266–77 . July 2000 . 10918583 . 10.1038/sj.onc.1203634 . 17891130 .
  69. Guo Q, Xie J, Dang CV, Liu ET, Bishop JM . Identification of a large Myc-binding protein that contains RCC1-like repeats . Proceedings of the National Academy of Sciences of the United States of America . 95 . 16 . 9172–7 . August 1998 . 9689053 . 21311 . 10.1073/pnas.95.16.9172 . 1998PNAS...95.9172G . free .
  70. Taira T, Maëda J, Onishi T, Kitaura H, Yoshida S, Kato H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H . AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC . Genes to Cells . 3 . 8 . 549–65 . August 1998 . 9797456 . 10.1046/j.1365-2443.1998.00206.x . 41886122 . free .
  71. Li H, Lee TH, Avraham H . A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer . The Journal of Biological Chemistry . 277 . 23 . 20965–73 . June 2002 . 11916966 . 10.1074/jbc.M112231200 . free .
  72. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, Funa K . Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor . Journal of Cell Science . 114 . Pt 8 . 1533–44 . April 2001 . 10.1242/jcs.114.8.1533 . 11282029 .
  73. Taira T, Sawai M, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H . Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y . The Journal of Biological Chemistry . 274 . 34 . 24270–9 . August 1999 . 10446203 . 10.1074/jbc.274.34.24270 . free .
  74. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K . p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression . The Journal of Biological Chemistry . 277 . 35 . 31694–702 . August 2002 . 12080043 . 10.1074/jbc.M200266200 . free .
  75. Liu X, Tesfai J, Evrard YA, Dent SY, Martinez E . c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation . The Journal of Biological Chemistry . 278 . 22 . 20405–12 . May 2003 . 12660246 . 4031917 . 10.1074/jbc.M211795200 . free .
  76. Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H . MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc . The Journal of Biological Chemistry . 273 . 45 . 29794–800 . November 1998 . 9792694 . 10.1074/jbc.273.45.29794 . free .
  77. Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, Nagashima K, Ariga H . MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer . The Journal of Biological Chemistry . 276 . 48 . 45137–44 . November 2001 . 11567024 . 10.1074/jbc.M106127200 . free.
  78. Park J, Wood MA, Cole MD . BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation . Molecular and Cellular Biology . 22 . 5 . 1307–16 . March 2002 . 11839798 . 134713 . 10.1128/mcb.22.5.1307-1316.2002 .
  79. Fuchs M, Gerber J, Drapkin R, Sif S, Ikura T, Ogryzko V, Lane WS, Nakatani Y, Livingston DM . The p400 complex is an essential E1A transformation target . Cell . 106 . 3 . 297–307 . August 2001 . 11509179 . 10.1016/s0092-8674(01)00450-0 . 15634637 . free .
  80. Feng XH, Liang YY, Liang M, Zhai W, Lin X . Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B) . Molecular Cell . 9 . 1 . 133–43 . January 2002 . 11804592 . 10.1016/s1097-2765(01)00430-0 . free .
  81. Otsuki Y, Tanaka M, Kamo T, Kitanaka C, Kuchino Y, Sugimura H . Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts . The Journal of Biological Chemistry . 278 . 7 . 5132–40 . February 2003 . 12446731 . 10.1074/jbc.M206733200 . free .
  82. Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R, Eilers M . Transcriptional activation by Myc is under negative control by the transcription factor AP-2 . The EMBO Journal . 14 . 7 . 1508–19 . April 1995 . 7729426 . 398238 . 10.1002/j.1460-2075.1995.tb07137.x.
  83. Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, Olejniczak ET, Clark T, Dey S, Lorey S, Alicie B, Howard GC, Cawthon B, Ess KC, Eischen CM, Zhao Z, Fesik SW, Tansey WP . Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC . Molecular Cell . 58 . 3 . 440–52 . May 2015 . 25818646 . 4427524 . 10.1016/j.molcel.2015.02.028 .
  84. Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K . Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc . Science . 262 . 5141 . 1889–92 . December 1993 . 8266081 . 10.1126/science.8266081 . 1993Sci...262.1889S .
  85. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Möröy T, Bartek J, Massagué J, Hänel F, Eilers M . Repression of p15INK4b expression by Myc through association with Miz-1 . Nature Cell Biology . 3 . 4 . 392–9 . April 2001 . 11283613 . 10.1038/35070076 . 12696178 .
  86. Peukert K, Staller P, Schneider A, Carmichael G, Hänel F, Eilers M . An alternative pathway for gene regulation by Myc . The EMBO Journal . 16 . 18 . 5672–86 . September 1997 . 9312026 . 1170199 . 10.1093/emboj/16.18.5672 .
  87. Web site: PSICQUIC View. ebi.ac.uk. 2019-05-02.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Myc".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.